LLY Eli Lilly and Co
- 781.100
- +43.900+5.95%
- 772.080
- -9.020-1.15%
Eli Lilly and Co News
Eli Lilly and Co | 8-K: Current report
Eli Lilly and Co | DEFA14A: Others
Eli Lilly and Co | DEF 14A: Definitive information statements
Eli Lilly and Co | PRE 14A: Preliminary proxy statements relating to merger or acquisition
Eli Lilly and Co | 8-K: Entry into an Underwriting Agreement
Eli Lilly and Co | 8-K: Eli Lilly and Co Reports Fourth Quarter 2023 Financial Results and Provides 2024 Financial Guidance
Eli Lilly and Co | 8-K: Eli Lilly and Co Reports Third Quarter 2023 Financial Results
Eli Lilly and Co | 8-K: Eli Lilly and Co Reports Second-Quarter 2023 Financial Results
Eli Lilly and Co | 8-K: Voting results 2023 Annual Meeting of Shareholders
Eli Lilly and Co | 8-K: Eli Lilly and Co Reports First-Quarter 2023 Financial Results
Eli Lilly and Co | DEFA14A: Others
Eli Lilly and Co | DEF 14A: Definitive proxy statements
Eli Lilly and Co | 8-K: Eli Lilly entered into a non-competition agreement with Daniel Skovronsky
Eli Lilly and Co | 8-K: Eli Lilly and Co entered into an underwriting agreement
Eli Lilly and Co | PRE 14A: Preliminary proxy statement not related to a contested matter or merger/acquisition
Eli Lilly and Co | 8-K: Lilly Reports Fourth-Quarter 2022 Financial Results, Core Business Growth and Pipeline Advancements Support Strong Long-Term Outlook
Eli Lilly and Co | 8-K: Eli Lilly and Co Announces 2023 Financial Guidance and Plans to Launch up to Four New Medicines
Eli Lilly and Co | 8-K: Lilly Reports Solid Third-Quarter 2022 Financial Results and Continued Pipeline Progress
Eli Lilly and Co | 8-K: Estimated Third Quarter Acquired In-Process Research and Development and Development Milestone Charges
Eli Lilly and Co | 8-K: Current report
Analysis
Price Target
No Data
